
I-Mab – NASDAQ:IMAB
I-Mab stock price today
I-Mab stock price monthly change
I-Mab stock price quarterly change
I-Mab stock price yearly change
I-Mab key metrics
Market Cap | 74.48M |
Enterprise value | N/A |
P/E | -0.83 |
EV/Sales | -2.04 |
EV/EBITDA | -18.42 |
Price/Sales | 1.90 |
Price/Book | 0.73 |
PEG ratio | N/A |
EPS | -43.75 |
Revenue | -1.75B |
EBITDA | -3.33B |
Income | -3.34B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 7.93% |
Oper. margin | -11.56% |
Gross margin | 0% |
EBIT margin | -11.56% |
EBITDA margin | 190.19% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeI-Mab stock price history
I-Mab stock forecast
I-Mab financial statements
Jun 2022 | 8.00M | -161.53M | -2018.7% |
---|---|---|---|
Dec 2022 | -1.76B | -2.97B | 168.77% |
Jun 2023 | 2.83M | -111.49M | -3931.8% |
Dec 2023 | 1.10M | -95.73M | -8673.15% |
2025 | 38.80M | -7.57B | -19515.09% |
---|---|---|---|
2026 | 51.74M | -8.71B | -16844.84% |
2027 | 21.42M | -599.65M | -2798.73% |
2028 | 21.42M | -634.49M | -2961.34% |
Analysts Price target
Financials & Ratios estimates
Payout ratio | 0% |
---|
2019 | 1.89% |
---|---|
2020 | |
2021 | |
2022 | |
2023 |
May 2023 | 3511695000 | 1.06B | 30.32% |
---|---|---|---|
Jun 2023 | 3511695000 | 1.06B | 30.32% |
Sep 2023 | 2612967000 | 894.81M | 34.25% |
Dec 2023 | 2612967000 | 894.81M | 34.25% |
Dec 2021 | -1.98B | -781.68M | 53.84M |
---|---|---|---|
Jun 2022 | -85.45M | 77.04M | 2.78M |
Dec 2022 | -2.11B | 403.90M | -2.78B |
Jun 2023 | 0 | 0 | 0 |
I-Mab alternative data
Aug 2023 | 378 |
---|---|
Sep 2023 | 378 |
Oct 2023 | 378 |
Nov 2023 | 378 |
Dec 2023 | 378 |
Jan 2024 | 378 |
Feb 2024 | 378 |
Mar 2024 | 378 |
Apr 2024 | 378 |
May 2024 | 378 |
Jun 2024 | 378 |
Jul 2024 | 220 |
I-Mab other data
Patent |
---|
Grant Utility: Anti-PD-L1 antibody and IL-7 fusions Filling date: 25 Jan 2019 Issue date: 2 Aug 2022 |
Application Filling date: 28 Dec 2021 Issue date: 21 Apr 2022 |
Application Filling date: 27 Jul 2020 Issue date: 14 Apr 2022 |
Grant Filling date: 12 Aug 2020 Issue date: 1 Mar 2022 |
Application Filling date: 15 Feb 2019 Issue date: 24 Feb 2022 |
Grant Filling date: 29 Mar 2019 Issue date: 11 Jan 2022 |
Grant Utility: Human PD-L1 antibodies Filling date: 26 Apr 2020 Issue date: 28 Dec 2021 |
Application Filling date: 12 Jul 2021 Issue date: 11 Nov 2021 |
Application Filling date: 12 Aug 2020 Issue date: 14 Oct 2021 |
Application Filling date: 20 May 2021 Issue date: 16 Sep 2021 |
Quarter | Transcript |
---|---|
Q2 2023 17 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q4 2022 31 Mar 2023 | Q4 2022 Earnings Call Transcript |
Q4 2021 29 Mar 2022 | Q4 2021 Earnings Call Transcript |
Q2 2021 31 Aug 2021 | Q2 2021 Earnings Call Transcript |
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
Week In Review: Adlai Nortye Stages $97.5 Million U.S. IPO On NASDAQ
I-Mab: Why This Company Trades At A Third The Value Of Its Cash
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Week In Review: METiS, A U.S.-China AI Biotech, Acquires Pan-RAF Inhibitor In $482 Million Deal
Week In Review: Biocytogen, A Genetically Modified Animal Models Company, Stages $60 Million IPO
Week In Review: China And The U.S. May Settle De-Listing/Accounting Impasse
I-Mab Valuation Offers A Biotech Investment Opportunity
-
What's the price of I-Mab stock today?
One share of I-Mab stock can currently be purchased for approximately $4.06.
-
When is I-Mab's next earnings date?
Unfortunately, I-Mab's (IMAB) next earnings date is currently unknown.
-
Does I-Mab pay dividends?
No, I-Mab does not pay dividends.
-
How much money does I-Mab make?
I-Mab has a market capitalization of 74.48M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 112.48% to 27.64M US dollars.
-
What is I-Mab's stock symbol?
I-Mab is traded on the NASDAQ under the ticker symbol "IMAB".
-
What is I-Mab's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of I-Mab?
Shares of I-Mab can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does I-Mab have?
As Jul 2024, I-Mab employs 220 workers, which is 42% less then previous month and 42% less then previous quarter.
-
When I-Mab went public?
I-Mab is publicly traded company for more then 5 years since IPO on 17 Jan 2020.
-
What is I-Mab's official website?
The official website for I-Mab is i-mabbiopharma.com.
-
How can i contact I-Mab?
I-Mab can be reached via phone at +86 21 6057 8000.
I-Mab company profile:

I-Mab
i-mabbiopharma.comNASDAQ
34
Biotechnology
Healthcare
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Shanghai, 200124
CIK: 0001778016
ISIN: US44975P1030
CUSIP: 44975P103